Approved by the FDA in 2019, Spravato® (esketamine) is a novel treatment for depression that marks the first new psychiatric medication introduced in over three decades. It represents a pioneering approach to address depression, a condition that the World Health Organization has identified as the leading global cause of disability.
Spravato® offers hope to those with treatment-resistant depression (TRD) who have not found relief from conventional therapies and medications. Typically taken with an oral antidepressant, Spravato® can produce long-lasting results in just a few weeks.
Spravato® is based on ketamine, an anesthetic that can lead to a diminished or absent sense of pain. It boosts glutamate neurotransmitters to create and strengthen brain pathways to uplift mood and improve overall well-being.
As an in-network provider, Pacific Mind Health is proud to offer Spravato® as a compelling treatment alternative in Los Angeles and at our other California locations. Spravato® is a nasal spray that is self-administered in our office under medical supervision. , In most cases, treatment is covered by insurance, making this innovative therapy an affordable option…
Our expert team specializes in complex cases of depression. If you or a loved one is grappling with persistent symptoms of depression, Spravato® could be the solution you’ve been seeking. Schedule a consultation today. Call us at (310) 425-3881 or complete our online consultation form.
Ketamine has long been used as an anesthetic for its ability to rapidly induce a dissociative state that can reduce or eliminate the perception of pain. In therapy, ketamine allows patients to talk about difficult experiences without becoming overwhelmed with anxious thoughts and emotions.
Ketamine is employed in two ways:
Both forms of ketamine can affect brain receptors in different ways. Ongoing research is shedding light on the efficacy of each type as well as the side effects they may produce. At this time, Pacific Mind Health only offers Spravato® esketamine.
Treatment-resistant depression (TRD) is a challenging form of depression that can feel overwhelming. It often persists despite conventional treatments like therapy and antidepressants, leaving individuals grappling with despair and even thoughts of suicide. Recognizing the signs of TRD can be crucial. These include:
If you or someone you know is struggling with TRD or has experienced limited success with other treatments, ketamine therapy offers a ray of hope.
Individual treatment plans can vary depending on your specific needs. During your Spravato® treatment, you’ll self-administer the medication as a nasal spray three times, spaced five minutes apart. You will remain in our office under medical supervision for two hours to monitor for any potential side effects. You can pass the time by reading, listening to music, or watching television.
After your treatment session, it’s important to arrange for someone to drive you home. You are not allowed to operate a vehicle or machinery for the remainder of the day.
Treatment typically involves twice-weekly sessions for four weeks, followed by weekly sessions. Treatment frequency may be adjusted based on your response. As part of your treatment with Spravato®, you will also be prescribed an antidepressant. Individual experiences can vary. Some patients report positive changes within the first week, while other notice improvements in a few weeks.
Spravato® offers a lifeline to those who have been disheartened by ineffective traditional depression treatments. Explore the many benefits it offers:
Insurance Coverage: Our Spravato treatment center in Los Angeles is in-network with all major insurance carriers, many of which cover Spravato®, making it an affordable treatment for patients.
Tailored for TRD: For patients who have seemingly tried everything, Spravato® offers hope and an effective treatment to reduce and even eliminate symptoms.
Targeted Approach: Spravato® directly targets brain cells, stimulating them and leading to improvements in depression symptoms.
Spravato® is primarily designed for individuals diagnosed with treatment-resistant depression. This condition is defined as having tried at least two different antidepressant medications at adequate dosages and durations (6–8 weeks per medication) without achieving sufficient symptom relief. These individuals typically experience persistent depressive symptoms despite standard interventions.
Candidates must already be on a stable, active antidepressant regimen. Spravato® is used as an adjunctive therapy, meaning it is administered alongside their current antidepressant treatment. This ensures continuity in their overall depression management plan and maximizes the efficacy of Spravato.
Spravato® is generally approved for adults aged 18 years and older. While studies primarily focus on adult populations, clinical decisions for younger or older patients are made on a case-by-case basis, weighing the benefits against potential risks.
Spravato® is not suitable for all patients. Key contraindications include:
Candidates typically exhibit moderate to severe depressive symptoms that significantly impact their daily functioning or quality of life. This includes individuals with substantial functional impairment, difficulty maintaining employment or relationships, or a history of multiple depressive episodes that demonstrate the chronic nature of their condition.
Spravato® treatment involves a unique administration process and requires patient compliance and understanding. Candidates must:
Due to the nature of esketamine and its administration as a nasal spray, Spravato® must be administered in a certified medical setting under the direct supervision of trained healthcare professionals. Patients are closely monitored for adverse effects such as sedation, dissociation, or increases in blood pressure. This controlled environment ensures safety and immediate management of any complications.
Spravato® is a specialized treatment designed for carefully selected patients. By adhering to these criteria, healthcare providers can ensure that the therapy is both effective and safe for individuals who meet the outlined qualifications.
While ketamine has dissociative and hallucinogenic properties, the risk of addiction when used in a clinical, monitored setting is extremely low. As a Schedule III drug, ketamine has a much lower risk for dependency than morphine, heroin, and other substances. Furthermore, extensive research is underway to explore ketamine’s potential as a treatment for substance use disorders.
If you or someone you know has been grappling with depression, ketamine therapy offers a potential solution. At Pacific Mind Health, we are dedicated to providing this groundbreaking treatment in a safe and supportive environment. Join our waiting list today to embark on your journey toward Spravato therapy in Los Angeles.
Embark on your mental health journey and schedule a consultation today. Call us at (310) 425-3881 or complete our online consultation form.
Trusted Psychiatrists serving Long Beach, Los Angeles & Orange County. Contact us at (310) 425-3881. We offer TMS Treatment, Therapies and more.
